Brighter Future Today: Advocacy for HPV and Cervical Cancer Prevention across the Life Course
A necessary condition of cervical cancer is an infection so common almost every human will contract it in a lifetime: Human Papilloma Virus (HPV). Annually, 530,000 women are diagnosed with cervical cancer, and the majority of the 260,000 deaths are in LMIC. Despite WHO recommendations, fewer than 5% of 9-14 year-old girls have been fully immunized. Over 110 countries have yet to introduce the vaccine. As vaccine access slowly expands, it must be coupled to comprehensive, innovative, community-based disease prevention strategies – adoption of new technologies and policies, investment in community and frontline health workers, and scaling existing investments and programs. This session will provide updates in HPV vaccine science; implementation lessons; and strategic advocacy for introduction and scale-up of comprehensive cervical cancer prevention programs.
Mary Carol Jennings, IVAC, International Vaccine Access Center
Elizabeth Murphy, Jhpiego
Julie Wieland, Pink Ribbon Red Ribbon
Megan Wysong, Jhpiego